In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.
For years, the European Society of Cardiology (ESC) annual congress has stood as the most prominent international meeting in the field of cardiology.
In recent years, it has begun to take on the role of the foremost cardiology, regardless of location, and it appears the ESC is hoping this trend will continue as it prepares for the ESC Congress 2023, which will be conducted in Amsterdam and virtually from August 25-28, 2023. With thousands of unique abstracts and more than half a dozen hot line sessions planned for presentation, the meeting is expected to bring forth the latest advances across the spectrum of disciplines in cardiology.
In this episode of Don’t Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, codirector of the Center for Implementation Science at Brigham and Women’s Hospital, and Stephen Greene, MD, advanced heart failure specialist at the Duke Clinical Research Institute, sit down for a discussion surrounding the meeting itself and take a deep dive into 3 late-breaking trials from ESC Congress 2023: STEP HFpEF, HEART-FID, and the QUEST trials. Also included in this episode is a brief conversation on the topline results of the SELECT trial and what it means for management of cardiometabolic illness.
Vaduganathan reports having received funding for consulting or research grants from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others.
Greene reports having received funds for consulting or research grants from Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.